How does obesity impact cosentyx outcomes?

How does obesity change Cosentyx response in psoriasis and psoriatic arthritis?

Obesity is linked to lower PASI-75 and ACR-20 response rates in patients taking secukinumab. In pooled trial data, patients with BMI above 30 achieved roughly 10-15 percentage points lower skin-clearance scores than those with normal weight. Similar gaps appear in joint scores, though absolute numbers stay clinically meaningful for most.

Why does body weight reduce Cosentyx effectiveness?

Secukinumab is a fixed 300 mg monthly dose. Higher body mass increases drug clearance and lowers trough levels, so some obese patients fall below the exposure needed for full IL-17 blockade. Pharmacokinetic models show each 10 kg rise in weight shortens half-life by about 8 percent.

Do heavier patients need higher or more frequent dosing?

Label guidance does not recommend dose adjustment. Some clinicians split the 300 mg dose into two weekly 150 mg injections for the first month in patients over 100 kg, but randomized evidence for this approach remains limited.

What happens if patients lose weight while on Cosentyx?

Small observational studies report that a 5-10 percent drop in BMI during the first year correlates with an extra 8-12 point rise in PASI improvement. The effect is clearest when weight loss occurs early, before chronic inflammation resets.

Are there safety differences by weight?

Injection-site reactions and nasopharyngitis rates do not differ meaningfully by BMI. Serious infection risk stays low across weight categories, though absolute event counts are slightly higher in the obese subgroup simply because more patients are enrolled.

How do biosimilars or newer IL-17 agents compare in obese patients?

No head-to-head data exist yet. Bimekizumab and ixekizumab show similar exposure drops in high-BMI cohorts in their own trials, suggesting the pattern is class-wide rather than specific to secukinumab.